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Abstract 
Despite advancements in technology and medication therapy, coronary artery disease continues 
to remain the number one cause of death.  Treatment for coronary artery disease requires life 
style modifications, medication therapy, percutaneous coronary interventions, and sometimes 
coronary artery bypass surgery.  Though percutaneous coronary interventions are considered safe 
and are commonly occurring procedures, there are still risks for complications.  One of the most 
frequently occurring complications is hematoma of the femoral artery site.  The purpose of this 
study was to determine if there was an increased incidence of hematomas in individuals 
undergoing percutaneous coronary intervention with associated sheath times of less  than five 
hours (Group A) as compared to sheath time of greater than five hours (Group B).	  	  The study 
used a retrospective, two group design and was conducted at a tertiary care center that performs 
over 1500 PCI’s annually.  Inclusion criteria included adults over the age of 18 who were 
hemodynamically stable, had no known bleeding disorders, and were punctured once at  the 
femoral artery to perform the percutaneous intervention.  Two hundred fifty medical records 
were reviewed utilizing a data collection tool designed by the researcher.  Total sample size was 
55, 21 in Group A and 34 in Group B.  Six hematomas were documented as occurring, but were 
not reportable based on the ACC definition.  Hematomas were documented in the medical record 
using the terms “small”, “medium,” and “large” versus an objective measurement.  No 
hematomas were identified using the ACC definition, which was the measurement standard for 
this research hospital.  Sheath times in Group A averaged 4.02 hours, and group B 7.42 hours.  
There was a higher incidence of descriptive hematoma that did not meet the criteria of this study 
in Group B.  Results call for recommendations of on-going documentation of post procedure 
hematomas using a standardized, reliable, and valid measuring tool.  APRN’s can be 
instrumental in implementing change in patient care , hospital policy and on the national level by 
assuring that hematomas are accurately and consistently documented.  Further research is 
indicated related to sheath times and potential associated negative outcomes. 	  
Key words: Percutaneous coronary interventions, hematomas, femoral artery, sheath times, 
complications.  
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Background and Statement of the Problem 
Cardiac disease remains the number one cause of death in persons over the age of 75, and 
is ranked the number two cause of death in persons aged 25-74.  In the past 15 years, 
advancements in technology and medicine have led to a significant increase in the number of 
cardiac catheterizations and percutaneous coronary interventions (PCIs) that have been 
performed.  These include a broad category of procedures including angioplasty, placement of 
stents, artherectomy, laser treatment, cutting angioplasty, and brachytherapy (Shoulders-Odom, 
2008).  In the year 2006, there were over 1,300,000 PCI procedures performed in the United 
States (US).  These numbers are projected to increase with the aging of the population (American 
Heart Association [AHA], 2009).  Due to the increased proliferation of PCI procedures, hospitals 
capable of performing PCIs in the US have increased from 920 hospitals in 1993 to 1316 in 
2004.  PCIs receive generous reimbursement rates, and this, along with decreased federal 
regulatory processes, has led to the considerable increase in hospitals performing PCI procedures 
in the US (Girotra & Cram, 2012). 
The state of Rhode Island (RI) is approximately 1,045 square miles with a population of 
1,052, 067 (US Census Bureau, 2010).  Rhode Island is ranked 24th in the incidence of heart 
disease in the US, and in 2009 heart disease was listed as the number one cause of death in RI, at 
2,411 individuals (National Center for Health Statistics, 2010).  The state has 13 hospitals, of 
which two are psychiatric hospitals.  Of the remaining 11, eight are capable of performing 
cardiac catheterizations and three are licensed to perform PCIs (RI Department of Health, 2011).  
Cardiac catheterization, an invasive procedure, is commonly used diagnostically and 
therapeutically for evaluation of patients with symptomatic coronary artery disease (CAD) 
(Cosman, Arthur, & Natarajan, 2011).  When therapy is required for treatment of the CAD, a 
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PCI may be indicated.  A PCI is performed during a cardiac catheterization procedure, at which 
time a catheter with a balloon is advanced to the site of the lesion and a stent, a hollow mesh tube 
which is left in place to attempt to keep the vessel patent, is deployed.  Alternatively, a 
pertcutaneous transluminal coronary angioplasty (PTCA) may be performed, in which the 
balloon catheter is used to push the plague to the sides of the artery (McConnell et al., 2012). 
As an experienced nurse working in a diagnostic cardiac catheterization lab, the author 
has noted anecdotally that approximately 20% of patients require travel to another facility in 
order to undergo the PCI.  This requires that the sheath that was inserted into a major blood 
vessel in order to perform the catheterization must remain in place. There is some suggestion in 
the literature that the amount of time that a sheath remains in place may be associated with an 
increased risk of complications, including hematoma formation.  For patients that need to be 
transferred to another facility, transport time, availability of paramedic staffed ambulances, and 
arranging staff to travel with the patient impact the total time that the sheath remains in place.  In 
addition, a hemodynamically, asymptomatic patient who is transferred for PCI may be triaged to 
the end of the catheterization schedule, or postponed overnight, with the sheath remaining in 
place for an extended period of time.  Even in circumstances where the PCI is performed within 
one institution, various factors impact the total time of the procedure and sheath time, including 
the practitioners’ schedule, the institutions’ schedule, and or the institutions’ capability.    
The purpose of this study was to determine if there was an increased incidence of 
hematomas in individuals undergoing percutaneous coronary intervention with associated sheath 
times of greater than five hours as compared to sheath time of less than five hours.  
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Literature Review 
A review of the literature was conducted utilizing search engines Pub Med, and CINAHL 
databases. Key words searched and combined included cardiac catheterization, percutaneous 
coronary intervention, femoral complications, femoral sheaths, hematoma, and risk factors for 
vascular complications. Literature from the years 2000 to 2013 was searched.  Key literature will 
be presented and discussed.        
Approximately 80,000,000 American adults have one or more types of cardiovascular 
disease (CVD), which includes hypertension (HTN), coronary artery disease (CAD), heart failure 
(HF), stroke, and congenital cardiovascular defects.  Of the total, 38,100,000 are estimated to be 
age 60 years or older.  Approximately 2,400 Americans die every 37 seconds from CVD (AHA, 
2009).  Coronary artery disease (CAD) is a major cause of death and disability in industrialized 
countries.  CAD mortality rates have declined over the past four decades in the US, but still 
remain the number one cause of death (Rosamond et al., 2008 e25).  CAD is responsible for 
about one-third of all deaths in individuals over age 35, and it has been estimated that nearly one-
half of all middle-aged men and one-third of middle-aged women in the US will develop some 
manifestation of coronary artery disease (Lloyd-Jones et al., 2010). 
Epidemiology of Coronary Artery Disease   
Understanding of the pathophysiology of CAD has evolved throughout the 20th century.  
Once thought to be singularly a cholesterol building disease, the epidemiology of CAD has 
shifted to a complex interaction of risk factors and an inflammatory immune response within an 
arterial lumen.  In individuals with dyslipidemia, or concurrently with hypertension, when the 
arterial endothelium encounters certain bacteria, vasoconstrictor hormones augment the 
production of adhesion molecules that promote sticking of blood leukocytes to the inner surface 
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of the arterial wall.  What occurs next is highly related to the emerging risk factors for 
atherosclerosis, and the individual’s pathophysiological response.  Risk factors include, but are 
not limited to, high fat intake, obesity, hypertension, smoking, dyslipedemia, and genetics.  Once 
the changes begin to occur in the arterial wall, the blood lymphocytes, mainly phagocytes, and T 
cells, activate the inflammation cascade within the arterial wall and CAD changes commence. As 
this process continues to synthesize in the arterial lumen, other physiological changes and 
mediators continue to occur over time.  When the lumen completes the inflammation process, 
calcium deposits form within the lumen and remain there until the individual suffers an event 
such as a clot interacting in the narrow lumen (Libby & Theroux, 2005).  
Overall Management of Coronary Artery Disease  
The management of CAD consists of lifestyle modification, medication therapy, and 
surgical interventions.  Management begins with patient education by providing individuals with 
preventative strategies to decrease the risk of developing CAD.  Teaching and guidance 
regarding modification of an individual’s risk factor may include diet and exercise, weight 
modification, smoking cessation, and blood pressure control.  If modifications fail to improve an 
individual’s risk, medication therapy is prescribed (Smith Jar et al., 2006). 
Medication therapy is aimed at reducing the individual’s modifiable risk factors that have 
been shown to be a catalyst for development of CAD.  Therapy approaches focus on cholesterol 
and blood pressure management.  Target blood pressure and cholesterol values are based on the 
American College of Cardiology and the American Heart Association guidelines and the Joint 
National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure 
(JNC 7),; (Smith Jar et al., 2006;  US Department of Health and Human Services [USDHHS], 
2008)  
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The recommendations include total cholesterol below 200mg/dl with low-density 
lipoprotein (LDL) below 100 mg/dl, high- density lipoprotein (HDL) greater or equal to 60 
mg/dl, and triglycerides less than 150mg/dl.  When cholesterol values fail to fall within these 
ranges a statin, or a lipid lowering medication, is prescribed based on the individual’s results. 
Maintaining systolic blood pressure (SBP) less than 120-128, and diastolic of less than 80-89 
mm Hg, are essential components in the management of hypertension (Lichtenstien et al., 2006) 
Medication therapy begins with a thiazide diuretic, which is a medication targeted at inhibiting 
resorption of sodium and chloride ions at the distal convoluted tubules in the kidneys.  If thiazide 
therapy is not successful in achieving those desirable BP results, additional medications such as 
an angiotensin-converting enzyme inhibitor (ACE), and/or an angiotensin receptor blocker 
(ARB) should be added.  Other medications that might be used, based on the individuals CAD 
symptoms, include aspirin, nitrates (nitroglycerin), beta-blockers, and calcium channel blockers 
(USDHHS, 2008).    
If lifestyle modifications and medical management fail to prevent symptoms of CAD 
from prevailing and progressing, surgical intervention including, PCIs or coronary artery bypass 
surgery, are the final therapy options.  Patients requiring intervention, whether it is PCI or bypass 
surgery, can be grouped into three categories: individuals who are limited in their activities due 
to symptoms not responding to medical therapy; individuals whose anatomy of target vessels 
have been proven benefited by revasculization; and those who desire bypass surgery or 
intervention for an improved quality of life in which the are not achieve by medications alone 
(Alderman et al., 2004).   
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Vascular Complications of Interventional Treatment  
Cardiac catheterizations and PCIs are considered routine procedures with a low threshold 
for serious complications.  The rate of complications for diagnostic catheterization is no more 
than 1%, and the complication rate associated with PCI is 3%  Complications that can disturb a 
patient’s post procedure recovery, cause pain, and an increase in length of stay include vascular 
complications such as hematoma, pseudoaneurysm, arteriovenous fistula, peripheral artery 
occlusion, dissections, and retroperitoneal bleeding (Cale & Constantino, 2012).  Vascular 
complications alone have been reported from 0.1 % to up to 61%, depending on the definition of 
complications and covariates (Dumont, Keeling, Bourguignon, Sarembock, & Turner, 2006).   
The femoral artery site is commonly used for access over other arteries, and is recognized 
as the most common site of vascular complications (Patel et al., 2010).  Significant vascular 
complications such as hematoma that require blood transfusion remain one of the leading causes 
of morbidity after a PCI.  The American College of Cardiology (ACC) defines a significant 
hematoma as “a collection of blood under the skin measuring 10 cm or more, with a drop in 
hemoglobin of three grams, and requires transfusion for treatment with red blood cells or whole 
blood, and or requires procedural intervention such as surgery at the bleeding site to reverse or 
stop the bleeding, and or a prolonged hospital stay” (ACC, 2011 pg 73). 
Even though technological advances continue to grow in cardiac catheterization and PCI, 
vascular complications remains the most common complication with hematoma development 
after femoral artery puncture being the most frequent (Cosman et al., 2010).  Patients who 
experience hematomas in the groin may experience a decreased quality of life, pain, and often a 
tingling sensation in that extremity, which has been reported to last for months (Andersen, 
Bregendahl, Kaestel, Skriver, & Ravkilde, 2005).  
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Research examining vascular complications has focused on many different potential 
contributors including the size of the sheath, gender, body mass index (BMI), skill of the 
operator, location of the puncture, the use of Glycoprotein (GP) IIb/IIIa inhibitors, thrombin 
inhibitors, number of punctures, activated clotting time, method of compression, closure devices, 
length bed rest, renal failure, practitioners’ efficiency, and personnel removing sheath.  No one 
variable or combination has been identified as the significant cause of hematomas (Applegate et 
al., 2008; Berry, Kelly, Cobbe, & Eteiba, 2004; Doyle et al., 2007). 
Juran, Rouse, Smith, O’Brien, DeLuca, and Sigmon (1999) conducted a landmark 
descriptive correlational study involving 4010 subjects.  The objective of the study was to 
measure the relationship between nursing interventions and vascular complications at the arterial 
access site in patients who underwent PCIs.  The authors also proposed to recommend a standard 
of care that minimized bleeding complications.  The Juran et al. study was a comprehensive 
research study that integrated nursing research, physicians, and a pharmaceutical company to 
develop a nursing sub study group within a company sponsored, clinical trial.  The main trial was 
titled Integrilin to Manage Platelet Aggregation to Prevent Coronary Thrombus (IMPACTII) 
and the nursing sub study was titled Standards of Angioplasty Nursing Techniques to Diminish 
Bleeding around the Groin (SANDBAG).  The study had two goals.  The first goal was to 
determine the current patterns of nursing practice after PCI.  That goal was accomplished by a 
survey and assessment of standards for patient care at 82 sites participating in IMPACTII study.  
The second and most significant goal in the SANDBAG study was to implement nursing 
recommendations based on the evidence of the large, randomized clinical trail.   
The SANDBAG study was one of the first studies to acknowledge the effects of evidence 
based practice on nursing standards, and the effect the changes had on decreasing post PCI 
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complications. The study implemented protocols for measuring activated clotting times at the 
bedside before sheath removal, discontinuing heparin after sheath removal, and decreasing use of 
heparin infusions in appropriate patients after PCIs.  Early sheath removal was noted as a 
significant factor in decreasing bleeding complications at the arterial site.  Results compared 
earlier sheath pull versus later sheath pull and demonstrated a decrease of 5% in bleeding 
complications and a decrease in length of stay by 1.7%.  Results demonstrated a bleeding rate of 
5.4% (n= 51/941) for sheath times < 7.1 hours as compared to 10.3% (n=97/943) for sheath 
times < 23.7 hours. This finding demonstrated that longer sheath times were related to higher 
bleeding complications (Juran et al., 1999).  
Berry et al.  (2004) conducted a single correlation observational study over a three month 
period.  The study researched the nature and incidence of arterial puncture complications from 
coronary angiograms and PCIs in clinical practice.  The premise of this project was based on the 
underreporting of hematomas post coronary angiogram and PCIs, and the substantial amount of 
hospital expenditures that may arise from these complications.  The study calculated sheath times 
as a variable during the length of the procedures, not the total sheath time.  Three hundred eleven 
consecutive procedures were included, of which 237 were coronary angiograms and 74 were 
PCI; 309 procedures (99%) involved femoral arterial access.  Data included the use of 
clopidogrel, low molecular weight heparin, unfractioned heparin, glycoprotein IIb/IIIa inhibitor 
therapies, aspirin, and blood pressure measurements.  A study sheet was attached to admission 
booklets for the staff to complete on each patient during an eight week period.   
The definition of hematoma used was a swelling around the arterial puncture site. 
Hematomas were categorized as being <5 cm, or > 5cm. by using an annotated ruler for 
measurement.  The Pearson Chi-Square test was used to compare categorical data.  Univiarate 
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and multivariate predictors of bleeding complications were determined by regression analysis.  
The data illustrated the percentage of hematomas rates for coronary angiogram and. PCIs.  
Sheath  times were longer for PCI’s than for coronary angiograms (191+-108 minutes versus 
49+-54  minutes) (p<0.00001).  The hematomas recorded for > 5cm were 11% (n=8) in PCI and 
6% (n=14) in coronary angiograms.  Hematomas recorded for < 5cm were 31% (n=22) for PCI 
and 17% (n=40) for coronary angiogram. The largest percent of hematomas was for PCIs at 41 
%( n =73), whereas coronary angiograms were calculated at 22% (n=56).  The study alluded 
more to the variables of female gender, increased BMI, and increased catheter size as the 
significant risk factors in causing hematomas, rather than sheath times.   
Andersen et al. (2005) conducted an audit to examine the incidence of hematomas after 
coronary angiograms and PCI’s via the femoral artery, and identified predictors that increased 
the risk for developing hematomas.  The audit included 474 medical records during a four month 
period.  Three hundred and twenty two subjects underwent coronary angiogram, 141 underwent 
PCI, and 11 were excluded due to missing data. Approximately 85% of the procedures were 
made via the femoral artery, 10% via the radial, and 5% the brachial.  A hematoma was defined 
as an accumulation of blood at the skin level with a diameter of >5 cm in the area of artery 
puncture.  The hematoma was always assessed by two nurses and/or a nurse and a doctor for 
reliability.  Twelve risk factors were identified among the 33 variables, with the most significant 
identified as the artery access.  The research emphasized the importance of an experienced 
operator and acknowledged that an experienced operator will also be able to reduce sheath time 
as well.  The study (n=463) demonstrated that the frequency of hematomas was 1.3 %( n=6) that 
were >10 cm, and 8.9 % (n=41) >5 cm.    
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The results were further categorized according to coronary angiogram or PCI.  The risk 
of hematoma for coronary angiograms was 7.5 %, and 12.1% with PCI’s.  The data was 
comparable to similar studies, but significantly higher than the American College of Cardiology 
incidence for complications (1% for coronary angiograms and 3 % for PCI).  The risk factors 
that were identified for developing a hematomas were female, multiple arterial punctures, active 
clotting time (ACT) time > 175 seconds, systolic blood pressure >160mm Hg, inexperienced 
operator, personnel changes during compression, use of 11b-11Ia inhibitors,  use of anti-
coagulation treatment, and sheath time greater than 16 minutes. These risk factors all provide 
background for changes in nursing procedures.  The research provided actual documented data 
related to the importance of decreased sheath time, and labeled increased sheath time as a 
possible risk factor for developing hematomas.  The data demonstrated a need to focus more care 
on patients that are at an increased risk for developing hematomas both in the cardiac 
catheterization lab and on the nursing units.  Utilization of the data collected enabled changes to 
be made to remove sheaths more efficiently in order to decrease the risk for hematomas 
(Andersen et al., 2005).  
Applegate et al. (2008) conducted a single-center observational study to evaluate if 
strategies to reduce vascular complications from sheath placement at the femoral artery in the 
past decade have improved. Strategies included the use of fluoroscopy to guide femoral artery 
access, utilization of vascular closure devices, and the use of smaller sheath size.  The study was 
conducted over a ten year period form 1998-2007.  The participants included a total of 35,016 
subjects undergoing consecutive diagnostic cardiac catheterization (n=20,777) and PCI 
(n=14,239).  The majority of the procedures (99%) were performed via the femoral artery.  
Annual rates of vascular complications were evaluated.  Covariate effects on the risk of vascular 
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complications were evaluated by logistic regression and risk-adjusted trend analysis.  The study 
provided significant background information related to complications after coronary angiograms 
and PCIs.  All sheaths were reported as removed soon after the procedure, with no specific time 
measurement as to how soon a sheath was removed.  Guidelines were provided to assist the 
practitioner to decide when the sheath could be pulled including activated clotting time less than 
or equal to 180 seconds in subjects who received heparin and greater or equal to 2 hours in 
subjects who received angiomax.  Subjects who did not receive closure devices had the sheath 
pulled when the activated clotting time (ACT) was less than or equal to 180 seconds.  Subjects 
who received either heparin or bilvalirudin had their sheaths pulled within two hours of the 
discontinuation of the infusion.   
The results of the study noted earlier sheath removal as one of the possible variables that 
contributed to a significant decrease of vascular complication.  Comparing rates from the time 
periods of 1998 - 2007, catheterization association complications were 1.7% to 0.2 % 
respectively and with PCIs from 3.1% to 1.0% respectively (p<0.001).  A decrease in hematomas 
>10 cm accounted for the greatest reduction in vascular complication rates: 1.1% (n= 47) in 1998 
to 0.3 % (n=2) in 2007 (p<0.001).  Results suggest that sooner sheath removal time is a positive 
factor decreasing vascular complications, and decreased sheath size was beneficial in decreasing 
vascular complications.  Female gender, decrease in body mass index (BMI), and larger sheath 
size were discussed as co-variates that led to an increase in complication rates. For coronary 
angiography, the risk of vascular complications was lower for 4-french size as compared to other 
larger sheath sizes.  PCI sheath size of 6-7 french had similar reported risk for vascular 
complications but risk was less than that for 8 and 10 french sheath sizes.  The study provided 
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valuable data related to changes in  practice that were implemented to aid in hematoma 
prevention, but a limitation was that specific sheath times were lacking.   
Doyle et al. (2008) conducted a quantitative non-experimental study that evaluated major 
vascular complications in three groups of subjects.  A total of 17,901 patients underwent PCIs. 
Group I (n = 2,443) received extensive anticoagulation and antiplatelet therapy before and during 
PCIs as well as dextran, warfarin, heparin, aspirin and dipyridamole.  Group II (n = 6,212) 
received anti platelet combination therapy including aspirin and ticlopidine, and peri procedural 
(GP) IIb/ IIIa inhibitors. Group III (n = 9,253) received aspirin and clopidogrel, along with (GP) 
IIb/IIIa inhibitors but at a reduced intensity and duration of the medications.       
The study reviewed changes that had occurred in anticoagulation protocols, antiplatelet 
therapies, and procedure time and evaluated if the changes lead to decreased rates in vascular 
complications.  Hematomas were considered major vascular complications.  Defining 
characteristics of the hematoma were identified as greater than four centimeters in diameter and 
those that required blood transfusion therapy.  The study evaluated procedural characteristics 
such as reduction sheath size, mean procedure time, and the dosing and duration of 
anticoagulation with heparin.  The study concluded that reduced sheath size, careful monitoring 
of anticoagulation and platelet inhibitors, along with the practitioners’ efficiency led to a 
decrease of vascular complications. Group I demonstrated an 8.4% reduction in hematomas 
(n=2,441) with 172 femoral hematomas; Group II had a 5.3% reduction (n=6,207) with 236 
femoral hematomas; and Group III yielded a 3.5% reduction (n=9,253) with 257 hematomas for 
vascular complications.  Results demonstrated a decrease in vascular complcations of 4.9% 
(n=17,901) across the three groups.  Minimized sheath dwell time was described as a 
contributing factor to the decline in major vascular complications, with the duration of 
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procedures time decreasing from 1.7 hours to 1.4 hours.  The study provides documentation that 
decreased sheath time during procedures has a positive affect on decreasing vascular 
complications, specifically hematomas.  The authors infer that decreased sheath time may be 
beneficial to decreasing risk of hematomas (Doyle et al., 2007). 
In conclusion, the importance of early sheath removal has been shown to be beneficial on 
decreasing hematomas in patients after PCIs.  The literature demonstrated an increase risk for 
developing hematomas in female gender, increased BMI, and large sheath sizes.  Smaller sized 
catheters, increased efficiency of the practitioners, and shorter procedure times were shown to be 
beneficial in decreasing hematomas.  The literature also includes the standardized testing of the 
activated clothing time and minimal use of thrombin inhibitors in providing criteria for when it is 
safe to remove a sheath.  However, the literature lacks consistent data specific to sheath dwell 
and removal time. 
Next, the theoretical framework used to guide this research project will be introduced.   
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Theoretical Framework 
The Theory of Unpleasant Symptoms, originally published in 1995 (Lenz, Suppe, Gift, 
Pugh, & Milligan), and then updated in 1997 (Lenz et al.), will be used as the theoretical 
framework to guide this research.  The Theory of Unpleasant Symptoms is a middle range 
theory, and was developed to guide nursing research and practice across multiple clinical 
populations.  Middle range theories were a change from the earlier grand nursing theories, which 
had been described more as blueprints for nursing than as potential guidelines for practice.  The 
Theory of Unpleasant Symptoms design was intended to assist nurses in symptom management, 
with the goal of linking nursing practice to research.  The theory proposes that each individual 
processes an unpleasant symptom in a different manner, and that an individualized plan of care 
to help prevent the symptoms from occurring is necessary in caring for the patient (Lenz et al., 
1995). 
Lenz et al. (1997) suggested that the patients ‘symptoms are caused by various factors 
including physiological, psychological, and/or situational factors.  The theory requires nursing to 
evaluate and identify the factors and acknowledge that they are interrelated.  Lenz et al. (1995) 
described the symptoms in terms of duration, intensity, distress, and quality.  This theory 
acknowledges a link between the three factors and how they interact in an individual and may 
lead to a possible negative affect on the individual’s experience.  This in turn can lead to 
alteration in an individual’s cognitive, functional, or physical performance.  
The Theory of Unpleasant Symptoms was used to guide proposed research study.  The 
study examined the unpleasant symptom of hematomas formation in post PCI patients.  
Hematomas may be caused by outside situational factors such as increased sheath time, which 
was the focus of this study.  This author proposed that the length of time a sheath remains in 
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place may lead to the physiologic process of hematoma development.  This in turn causes an 
increase in the patient’s pain and anxiety.  Alterations in situational factors may result, such as a 
delay in their ability to return to work, or home, and an alteration in current role.  The most 
common residual effects of the hematoma were inability to walk normal and unpleasant tingling 
sensation in the leg (Andersen et al., 2005).  Hematomas impact the patient’s well being, and in 
many cases may be preventable after PCI.    
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Methodology	  
Purpose 
The purpose of this study was to determine if there was an increased incidence of 
hematomas in individuals undergoing percutaneous coronary intervention with associated sheath 
times of greater than five hours as compared to sheath time of less than five hours.  It was 
proposed that those individuals whose sheath time was greater than five hours would have a 
higher risk for developing a hematoma.  
Research question  
The research question was: Does prolonged femoral sheath time of greater than five 
hours increase a patients’ risk for developing a hematoma formation after a PCI?  
Design 
The project employed a retrospective two group design.  Group A (control) included 
subjects who met the inclusion criteria and had their femoral sheath removed within five hours of 
insertion.  Group B (experimental group) included subjects who met the inclusion criteria and 
had the femoral sheath removed greater than five hours from time of insertion. 
Site 
The data collection took place at a tertiary care center in Providence, Rhode Island. The 
research hospital is a private, not for profit hospital that is licensed for 247 patient beds. The 
research hospital is a major teaching affiliate of the Warren Alpert Medical School of Brown 
University specializing in Cardiac Care. The research hospital performed approximately 1500 
PCIs last year. 
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 Sample 
The sample was recruited from the data base of patients who have had PCIs completed at 
the research hospital.  Inclusion criteria included subjects over the age of 18 who required an 
elective PCI procedure following a cardiac catheterization.  Exclusion criteria included 
procedures not accessed via the femoral artery, patients with known bleeding disorders, and 
multiple puncture attempts to the artery, those who developed an immediate hematoma, 
emergent PCI procedure, and also hemodynamic instability before, during, or after the PCI. 
Measurement   
A data collection tool (Appendix A) was designed by the student researcher based on the 
literature and clinical experience.  After IRB approval, the tool was pilot tested to assure 
completeness and usability.  Basic demographic data and data specific to the PCI were collected.  
Procedures 
Upon approval by the Lifespan and Rhode Island College IRB’s, the researcher obtained  
a list of all potential subjects who had undergone a PCI between January and June of 2012  at the 
study site and with a medical record  ICD-9 (International Classification of Diseases Codes, 
2010) of V4582.  The list was obtained from the quality control and assurance coordinator 
manager. No personal health information collected was electronically linked, and the list was 
destroyed upon completion of the data collection.  De-identified data were entered into an excel 
spread sheet. All data obtained was stored in a locked file to which only the researcher and 
faculty advisor had access to, and confidentiality of all data was maintained. 
Data were collected by the student researcher. Approximately 250 medical records were 
reviewed to obtain a cohort of 55.  Data were obtained from the documentation in the patients’ 
cardiac catheterization record/medical record.  Documentation of a hematoma was based on the 
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definition of the American College of Cardiology (ACC).  The ACC defines a hematoma “as a 
collection of blood under the skin measuring 10 centimeters or more, with a drop in hemoglobin 
of three grams, and requires transfusion for treatment of red blood cells, and or requires 
procedural intervention such as surgery at the bleeding site to reverse or stop the bleeding” 
(ACC, 2011, p. 73).  Upon review of the medical records, it was identified that actual 
measurement of hematomas post procedure was inconsistent.  Documentation of hematomas was 
limited to descriptive data, such as using the terms “small”, “medium,” and “large” to describe 
the size  Recognizing that the institution’s official counting of hematoma incidence was limited 
to the ACC definition, the student researcher determined that hematomas documented in the 
record that did not meet this definition were of interest to nursing practice.  For the purpose of 
attempting to quantify these hematomas, the student researcher designated a hematoma 
documented as “small” to be 2 cm. in size, a “medium” hematoma as 4 cm, and “large” 8 cm.  
Data Analysis 
Descriptive statistics were used to analyze the study variables, including frequencies, 
percentages, and mean scores.  Data were analyzed and compared by group, and group scores 
were further analyzed by gender.  Femoral sheath times greater than 5 hours versus sheath times 
less than 5 hours and the use of certain medications IIb/IIIa glycoprotein inhibitors; heparin, low 
molecular heparin, and thrombin inhibitors were analyzed regarding hematoma formation post 
PCI procedures.  
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Results 
A total of 250 medical records were reviewed to obtain a cohort of 55 subjects who 
underwent PCIs.  Group A, those individuals whose sheaths were in place for less than five 
hours, included 24 subjects; Group B, individuals whose sheath were in place for greater than 
five hours, included 31 subjects.  Exclusions included such factors as radial artery access, closure 
device usage within the femoral artery, and or hemodynamicaly instability patients before, 
during, or after the procedure. 
Demographic data by gender are listed in Table 1.  Data are presented by gender since 
gender is identified as a risk in the literature, with females at increased risk of hematoma post 
procedure.  Increased or decreased BMI for all genders has also been identified in the literature.   
Table 1 
Demographics Data by Gender  
Gender Number  Average 
Age  
Average 
Height 
(cm) 
Average 
Weight(kg) 
Average 
BMI 
Male 34 65 174 90 31 
Female 21 68 159 73 29.3 
 
The majority of the subjects were male.  Both genders had high BMI rates at 29-30% 
above target.  Average ages of the subjects were 65 years for males and 68 years for females’. 
Recommended BMI for adults > 20 years of age is less than or equal to 25 kg/m2 (AHA, 2012).  
Six French sheath size was used for all of the procedures except one. Figure 1 illustrates 
the ratio of male to female gender for each group in relation to the average length of time the 
femoral sheaths were in place.  
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Figure 1. Average length of time sheaths in place in relationship to Group A and Group 
B by gender. 
There were 16 males and eight females in Group A, and 18 males and 13 females in 
Group B.  The range of sheath time for Group A was 1.49 to 4.55 hours, with a mean sheath time 
of 4.02 hours.  Group B sheath time range was 5.07 to 13.33 hours, with a mean of 7.42 hours.   
No hematomas were identified using the ACC definition, which was the measurement standard 
for this research hospital.  The reported hematomas were lower than the national averages and 
the majority of the literature reviews noted in the study.  Seven charts of the 55 (12%) included 
descriptive documentation of hematomas by sheath removers who were nurse practitioners or 
cardiovascular technicians. These were characterized in the record as “small”, “medium”, and 
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“large”.  One hematoma was identified by the researcher as an outlier and was not included in 
the data collection results.  Table 2 illustrates the characteristics of the remaining six hematomas 
as well as the coagulation-impacting medications received by these subjects during the 
procedures.  The yellow shading illustrates those subjects who received both thrombin inhibitor 
and heparin.   
Table 2  
Descriptive Hematomas by Gender, Sheath Time, and Coagulation-Impacting Medications  
Subjects 
M=male 
F=Female 
Sheath 
times 
Hematoma 
Size 
Low 
molecular 
Heparin 
Heparin Thrombin 
inhibitor  
Glycoprotein 
11b-111a 
inhibitor  
1 – M 5.39 2.0 cm. No Yes Yes No 
2 – M 5.43 2.0 cm. No No Yes Yes 
3 – M 7.13 2.0 cm. No Yes No Yes 
4 – F 8.10 8.0 cm. No Yes Yes No 
5 – M 10.34 2.0 cm. No Yes No Yes 
6 – F 10.47 4.0 cm. No Yes No Yes 
 
Four (11%) males and two females (9 %) subjects developed hematomas.  Fifty percent 
of the six hematomas described in the record (n =3) received the thrombin inhibitor, angiomax, 
66% received a glycoprotein IIb-IIIa inhibitor –plavix (n= 4), and 83% (n = 5) received 
intravenous heparin.  The student researcher converted the documented hematomas from the 
chart as:  “small” = 2cm; “medium” = 4-6 cm; and “large” = 8cm.  Ten centimeters was not 
utilized as a description of large hematomas due to the fact that this would have qualified the 
patient for the ACC definition of hematoma and none of the patients were classified as having 
reportable hematomas.   
Greater than 80% of both groups (n =55) received heparin and a glycoprotein IIb-IIIa 
inhibitor, with group B being the highest at 94% (n=17) for the males and 92% (n=12) for 
females.  Thrombin inhibitors were utilized in both groups, with female subjects receiving the 
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least (12%; n= 1) in group A, and 7.6% (n=1) in Group B. Males received thrombin inhibitors at 
a higher rate (25%; n= 4) in Group A and Group B (27.7%; n= 5).  Low molecular weight 
heparin was not used in group A, and was used in low rates in Group B   
(7.6%; n= 1 females) (5.5%; n= 1 males).   
To further analyze contributors to prolonged sheath time, those subjects who were 
transferred from another facility were identified. Group A had one subject transferred from 
another facility (2.4%), with a sheath time of 3.50 hours; the remaining subjects in Group A who 
were not transferred from another facility had an average sheath times of 3.5 hours (n= 23; 95 
%).  In Group B, eight subjects (33 %) had been transferred from other facilities, with an average 
sheath time of 9.29 hours, while those in Group B who were not transferred had an average 
sheath time of 6.9 hours (n= 23; 74%). 
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Summary and Conclusions 
Cardiac disease remains the number one cause of death in persons over the age of 75, and 
is ranked the number two cause of death in persons aged 25-74.  Advancement in technology and 
medicine has lead to a significant increase in the number of cardiac catheterizations and PCIs 
performed in the past 15 years (Shoulders-Odom, 2008).  There were over 1,300,000 PCI 
procedures performed in the US in 2006 (AHA, 2009).  Hematomas are a complication that may 
occur as a result of these procedures.  The literature review provided data documenting a positive 
correlation between female gender, renal insufficiency, low BMI, high BMI, the use of certain 
thrombin inhibitors, and glycoprotein IIb/IIIa inhibitors as contributors to an increased risk factor 
in developing hematomas (Berry et al., 2004).  No single variable has been identified as the 
primary contributor to, nor has the literature directly identified sheath times as a causative factor.    
The purpose of this study was to determine if there was an increased incidence of 
hematomas in individuals undergoing percutaneous coronary intervention with associated sheath 
times of greater than five hours as compared to sheath time of less than five hours.  It was 
proposed that those individuals whose sheath time was greater than five hours would have a 
higher risk for developing a hematoma.  The study was guided by the theory of The Theory of 
Unpleasant Symptoms.  A retrospective chart review was conducted; 250 charts were reviewed 
of which 55 met the inclusion criteria.  Group A (n =24) included subjects whose sheath time 
was less than or equal to five hours.  Group B (n =31) were subjects whose sheath time was 
greater than five hours.  The data demonstrated a 0% hematoma rate in both groups per the ACC 
criteria. The rate of complications for diagnostic catheterization has been cited at 1% and 3% for 
PCI’s, but vascular complications alone have been reported from 0.1 % up to 61%, depending on 
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the definition of complications and covariates (Dumont, Keeling, Bourguignon, Sarembock, & 
Turner, 2006).   
Six descriptive documented hematomas were noted that did not meet the ACC criteria for 
hematoma. The six hematomas all had sheath times of greater than five hours, suggesting a 
potential relationship between prolonged sheath time and hematoma development.  In contrast to 
the literature, female gender was not found to be a contributing risk factor; the majority of 
documented hematomas occurred in males (n = 4; 66%).  Increased BMI was characteristic in 
both groups, consistent with the literature review.  Fifty percent of the six hematomas described 
in the record (n =3) received the thrombin inhibitor, angiomax, 66% received a glycoprotein 
IIb/IIIa inhibitor –plavix (n= 4), and 83% (n = 5) received intravenous heparin.  The literature 
review supported that the use of thrombin inhibitors and IIb/IIIa glycoprotein inhibitors as 
contributing factors in the development of hematomas.  
The student researcher speculated that the majority of individuals in Group B would have 
been transferred from other hospitals and would have subsequently had the PCI completed at the 
research hospital.  However, only 25 % (n =8) of those with sheath times of greater than five 
hours were transfers.  The majority of the patients started and completed their PCI’s at the 
research hospital.  This suggests that organizational factors contribute to the prolonged sheath 
dwell times.  As suspected, the majority of patients in group A began and completed their PCI’s 
at the research hospital (n = 1; 4 %).   
The study was limited by factors associated with a retrospective design. In particular, 
documentation in the medical records lacked reliability in regard to the manner in which 
hematomas were subjectively described.  A standard, reliable, and valid measure of hematoma 
size was not used to document hematoma size. The study was also limited by the small sample 
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size.  No attempt was make to collect other demographic data including race and ethnicity, so the 
impact of such variables cannot be identified. 
 In this study, all six subjects who experienced hematomas had sheath time of greater 
than five hours. Clearly, further study is indicated, also supported by the fact that actual 
documentation of sheath times in the literature is scant.  Results documented that those subjects 
who did experience hematoma had also received, IIb/IIIa glycoprotein inhibitors, and thrombin 
inhibitors.  No attempt was made to examine this relationship in subjects who did not develop a 
hematoma, and no conclusions can be drawn.  Hematomas after cardiac catheterization and PCI 
can produce significant, negative outcomes for patients, and further nursing research related to 
prevention, early detection, and management is needed.  
26 
 
Recommendations and Implications for Practice   
 
Advanced Practice Registered Nurses (APRNs) are called upon to lead by example and 
provide high quality nursing care.  Prevention and management of post cardiac intervention 
complications, including hematomas, is an important pursuit.  Specific to the findings in this 
study, APRNs can be instrumental in driving the development and implementation of evidence 
based protocols that include accurate documentation of hematomas.  Methods for assessing, 
recording, and documentating hematomas must be clearly specified and evidence based. 
Evidence based documentation drives practice improvement, and would be beneficial to 
both the institution and the patients receiving care.  Using a ruler is a simple, inexpensive, and 
validated tool that should be included as standard of care for documentation of any hematoma.  
Documentation of skin alterations is mandated by the Centers for Medicare and Medicaid 
Services (CMS), including size and descriptive adjectives that may be useful in defining and 
classifying the alteration.  A hematoma by definition is a collection of blood under the skin, and 
should be documented in the same manner as any other skin alteration.   
APRNs can continue to drive practice and policy change in their work place by being 
recognized leaders in such areas as evidence based practice councils and inter-disciplinary teams.  
APRN’s working in cardiac catheterization labs and cardiology should lobby to promote a 
standardized documentation method for hematoma measurements.  APRNs, as role models for 
practicing nurses, are in an excellent position to educate and demonstrate bedside nurses about 
the importance of hematoma assessment and accurate documentation.   
Further practice change and research is needed related to the length of time a sheath 
remains in place.  In addition to hematoma development, prolonged sheath time is associated 
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with all of the risks of immobility or prolonged bed rest, including increased pain, pressure 
ulcers, atelectasis, deep vein thrombosis, and difficulty voiding.  Prolong sheath time increases a 
patients’ exposure to all of the complications associated with immobility and can also lead to an 
increased length of stay.  APRNs should work with members of the inter-disciplinary team to 
examine organizational/systems issues that contribute to prolonged sheath times.  Once 
identified, and with needed administrative support, strategies to minimize modifiable factors can 
be implemented and evaluated.  Though it is not clear what the ‘ideal’ sheath dwell time is, the 
literature clearly supports that withdrawal as soon as is clinically feasible is indicated.  It is 
hypothesized that this is not a simply an issue at the study site; thus, lobbying for practice change 
at the national level through professional nursing organizations is warranted.  With a continuous 
increase in cardiac laboratories and advancements in interventional cardiology, these actions are 
necessary to ensure safety for our patients.  
Additional research related to the identification of minimal, ideal sheaths times is needed. 
In the literature, sheath times have been recorded from as little as 16 minutes and is this study 
sheath times of 1.49 hours to 13.33 hours were documented.  Prolonged sheath times when not 
clinically indicated are detrimental to quality patient care and need to be addressed through 
advanced nursing practice, education, policy change, and on-going research.  
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Appendix	  A	  
Data Collection Tool 
 
Age   
Gender   
Height   
 Weight   
Time femoral sheath is 
placed   
Time cardiac catheterization 
(CC)completed   
Is patient a transfer patient?   
Time patient arrived for 
percutanous coronary 
intervention(PCI)   
PCI start time   
PCI end time   
Sheath Size (Fr) 
 Time femoral Sheath 
Removed   
Length of time Sheath was 
in place    
Hematoma present -  per 
American College of 
Cardiology - NCDR 
Definition - Yes/No   
Hematoma Measurement in 
Centimeters    
Low Molecular Weight 
Heparin - Yes/No   
Heparin - Yes/No   
Thrombin Inhibitors - 
Yes/No   
Glycoprotein IIb-IIIa 
Inhibitors - Yes/No   
 
 
